Microporogen‐Structured Collagen Matrices for Embedded Bioprinting of Tumor Models for Immuno‐Oncology
Source abstract
Abstract
Abstract Embedded bioprinting enables the rapid design and fabrication of complex tissues that recapitulate in vivo microenvironments. However, few biological matrices enable good print fidelity, while simultaneously facilitate cell viability, proliferation, and migration. Here, a new microporogen‐structured (µPOROS) matrix for embedded bioprinting is introduced, in which matrix rheology, printing behavior, and porosity are tailored by adding sacrificial microparticles composed of a gelatin–chitosan complex to a prepolymer collagen solution. To demonstrate its utility, a 3D tumor model is created via embedded printing of a murine melanoma cell ink within the µPOROS collagen matrix at 4 °C. The collagen matrix is subsequently crosslinked around the microparticles upon warming to 21 °C, followed by their melting and removal at 37 °C. This process results in a µPOROS matrix with a fibrillar collagen type‐I network akin to that observed in vivo. Printed tumor cells remain viable and proliferate, while antigen‐specific cytotoxic T cells incorporated in the matrix migrate to the tumor site, where they induce cell death. The integration of the µPOROS matrix with embedded bioprinting opens new avenues for creating complex tissue microenvironments in vitro that may find widespread use in drug discovery, disease modeling, and tissue engineering for therapeutic use.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Cellular Mechanics and Interactions · Additive Manufacturing and 3D Printing Technologies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
John A. Paulson School of Engineering and Applied Sciences and the Wyss Institute for Biologically Inspired Engineering Harvard University Cambridge MA 02138 USA
École Polytechnique Fédérale de Lausanne Lausanne 1015 Switzerland
École Normale Supérieure de Lyon Lyon 69007 France
Department of Bioengineering Northeastern University Boston MA 02115 USA
Funding
National Cancer Institute
References (67)
Show source-provided references
1. 10.1126/sciadv.aaw245910.1126/sciadv.aaw2459 ↗
2. 10.1073/pnas.152134211310.1073/pnas.1521342113 ↗
3. 10.1002/adma.20130550610.1002/adma.201305506 ↗
4. 10.1126/sciadv.150065510.1126/sciadv.1500655 ↗
5. 10.1126/sciadv.150075810.1126/sciadv.1500758 ↗
6. 10.1126/science.aav905110.1126/science.aav9051 ↗
7. 10.1016/j.cell.2020.12.00210.1016/j.cell.2020.12.002 ↗
8. 10.1002/stem.197810.1002/stem.1978 ↗
9. 10.1038/nrc.2015.310.1038/nrc.2015.3 ↗
10. 10.1016/j.addr.2021.11400310.1016/j.addr.2021.114003 ↗
11. 10.1016/j.isci.2021.10217910.1016/j.isci.2021.102179 ↗
12. 10.1063/5.004232410.1063/5.0042324 ↗
13. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
14. 10.1073/pnas.141711511210.1073/pnas.1417115112 ↗
15. 10.1038/srep3158910.1038/srep31589 ↗
16. 10.1039/C6LC01422D10.1039/C6LC01422D ↗
17. 10.1038/nprot.2017.01810.1038/nprot.2017.018 ↗
18. 10.1158/2159-8290.CD-17-083310.1158/2159-8290.CD-17-0833 ↗
19. 10.1039/C8LC00322J10.1039/C8LC00322J ↗
20. 10.1038/s41551-019-0363-x10.1038/s41551-019-0363-x ↗
21. 10.1088/1758-5082/6/3/03500110.1088/1758-5082/6/3/035001 ↗
22. 10.1126/sciadv.abi911910.1126/sciadv.abi9119 ↗
23. 10.1038/nmat448910.1038/nmat4489 ↗
24. 10.1038/s41586-020-2612-210.1038/s41586-020-2612-2 ↗
25. 10.1088/1758-5090/7/3/03500610.1088/1758-5090/7/3/035006 ↗
26. 10.1002/adma.20180546010.1002/adma.201805460 ↗
27. 10.1002/adfm.20200374010.1002/adfm.202003740 ↗
28. 10.1021/acsami.7b1605910.1021/acsami.7b16059 ↗
29. 10.1126/sciadv.abc552910.1126/sciadv.abc5529 ↗
30. 10.1002/adhm.20220002710.1002/adhm.202200027 ↗
31. 10.1002/adma.20100462510.1002/adma.201004625 ↗
32. 10.1021/acsami.7b1981810.1021/acsami.7b19818 ↗
33. 10.1021/acsbiomaterials.6b0044410.1021/acsbiomaterials.6b00444 ↗
34. 10.1002/adfm.20190007110.1002/adfm.201900071 ↗
35. 10.1002/advs.20180107610.1002/advs.201801076 ↗
36. 10.1016/j.copbio.2018.11.00110.1016/j.copbio.2018.11.001 ↗
37. 10.1039/C8BM01286E10.1039/C8BM01286E ↗
38. 10.1039/D1BM00574J10.1039/D1BM00574J ↗
39. 10.1021/acsbiomaterials.0c0161210.1021/acsbiomaterials.0c01612 ↗
40. 10.1002/adma.20210919410.1002/adma.202109194 ↗
41. 10.1021/acsbiomaterials.6b0021810.1021/acsbiomaterials.6b00218 ↗
42. 10.1088/1361-6463/aae81310.1088/1361-6463/aae813 ↗
43. Morley C. D. · Int. J. Bioprint. · 2022 · 28
44. 10.1038/s41563-020-00803-510.1038/s41563-020-00803-5 ↗
45. 10.1002/smtd.20210007210.1002/smtd.202100072 ↗
46. 10.1097/00008505-200207000-0001410.1097/00008505-200207000-00014 ↗
47. 10.1016/j.ccr.2005.08.01010.1016/j.ccr.2005.08.010 ↗
48. 10.1016/j.cell.2009.10.02710.1016/j.cell.2009.10.027 ↗
49. 10.1016/j.copbio.2016.02.00710.1016/j.copbio.2016.02.007 ↗
50. 10.3390/biomedicines909113710.3390/biomedicines9091137 ↗
51. 10.1002/1522-2594(200006)43:6<828::AID-MRM8>3.0.CO;2-P10.1002/1522-2594(200006)43:6<828::AID-MRM8>3.0.CO;2-P ↗
52. 10.4161/cc.8.3.760810.4161/cc.8.3.7608 ↗
53. 10.1007/s00262-007-0286-310.1007/s00262-007-0286-3 ↗
54. 10.1083/jcb.20121015210.1083/jcb.201210152 ↗
55. 10.1097/CJI.0b013e31815c193f10.1097/CJI.0b013e31815c193f ↗
56. 10.1016/j.ccell.2017.04.00310.1016/j.ccell.2017.04.003 ↗
57. 10.1084/jem.2006189010.1084/jem.20061890 ↗
58. 10.1073/pnas.190385411610.1073/pnas.1903854116 ↗
59. 10.1016/j.immuni.2013.11.01710.1016/j.immuni.2013.11.017 ↗
60. Fu J. · Am. J. Transl. Res. · 2020 · 12 · 7262
61. 10.1080/2162402X.2019.159963510.1080/2162402X.2019.1599635 ↗
62. 10.3390/ijms2018450910.3390/ijms20184509 ↗
63. 10.1007/s00262-011-0984-810.1007/s00262-011-0984-8 ↗
64. 10.1038/s41598-017-10863-410.1038/s41598-017-10863-4 ↗
65. 10.1016/j.biomaterials.2013.11.03810.1016/j.biomaterials.2013.11.038 ↗
66. 10.1016/j.actbio.2018.07.03210.1016/j.actbio.2018.07.032 ↗
67. 10.1038/s41596-019-0144-810.1038/s41596-019-0144-8 ↗